0000000000336029

AUTHOR

Sylvie Escolano

showing 4 related works from this author

L’échantillon généraliste des bénéficiaires : un outil pour l’évaluation du risque vaccinal ?

2014

Introduction Les bases de donnees medico-administratives sont de plus en plus utilisees pour evaluer le risque vaccinal. L’echantillon generaliste des beneficiaires (EGB) a ete cree a partir de celle de l’Assurance-maladie par echantillonnage au 1/97 e de la population francaise. L’objectif de l’etude est de calculer pour differentes associations effet indesirable/vaccin un nombre de cas necessaires et de comparer ces effectifs avec ceux disponibles dans l’EGB. Methodes L’analyse en serie de cas est une approche frequemment utilisee pour ce type d’etude. Les effectifs ont ete calcules dans ce cadre, avec et sans prise en compte de l’effet âge. Pour l’association convulsion febrile (CF)/vacc…

EpidemiologyPublic Health Environmental and Occupational HealthRevue d'Épidémiologie et de Santé Publique
researchProduct

Validation of the French national health insurance information system as a tool in vaccine safety assessment: Application to febrile convulsions afte…

2013

In the French national health insurance information system (SNIIR-AM), routine records of health claimed reimbursements are linked to hospital admissions for the whole French population. The main focus of this work is the usability of this system for vaccine safety assessment programme. Self-controlled case series analyses were performed using an exhaustive SNIIR-AM extraction of French children aged less than 3 years, to investigate the relationship between MMR immunization and children hospitalizations for febrile convulsions, a well-documented rare adverse event, over 2009-2010. The results suggest a significant increase of febrile convulsions during the 6-11 days period following any MM…

RiskPediatricsmedicine.medical_specialtyNational Health ProgramsMeasles-Mumps-Rubella VaccinePopulationRate ratioSeizures FebrilePneumococcal conjugate vaccine03 medical and health sciences0302 clinical medicine030225 pediatricsProduct Surveillance PostmarketingAdverse Drug Reaction Reporting SystemsHumansMedicine030212 general & internal medicineeducationAdverse effectImmunization ScheduleComputingMilieux_MISCELLANEOUSeducation.field_of_studyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantICD-103. Good healthHospitalizationVaccinationInfectious DiseasesImmunizationChild PreschoolMolecular Medicine[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancebusiness[STAT.ME]Statistics [stat]/Methodology [stat.ME]Measles-Mumps-Rubella Vaccinemedicine.drug
researchProduct

SELPLG Gene Polymorphisms in Relation to Plasma SELPLG Levels and Coronary Artery Disease

2003

P-selectin and P-selectin glycoprotein ligand (SELPLG, selectin P ligand) constitute a receptor/ligand complex that is likely to be involved in the development of atherosclerosis and its complications. While the genetic variability of P-selectin has already been investigated in depth, that of the SELPLG gene has not yet been extensively explored. The coding and regulatory sequences of the SELPLG were screened and nine polymorphisms were identified. The identified polymorphisms were genotyped in the AtheroGene study, a case-control study of coronary artery disease (CAD). Haplotype analysis revealed that two polymorphisms of SELPLG, the M62I and the VNTR, independently influenced plasma SELPL…

AdultMalemedicine.medical_specialtyP-selectinEnzyme-Linked Immunosorbent AssayCoronary Artery DiseaseBiologyLigandsPolymerase Chain ReactionCoronary artery diseaseGene FrequencySELPLG GeneInternal medicineGeneticsmedicineHumansGenetic variabilityReceptorGenePolymorphism Single-Stranded ConformationalTriglyceridesGenetics (clinical)GeneticsMembrane GlycoproteinsPolymorphism GeneticHaplotypemedicine.diseaseP-SelectinCholesterolEndocrinologyHaplotypesRegulatory sequenceFemaleAnnals of Human Genetics
researchProduct

Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample.

2017

International audience; PurposeTo provide an up-to-date account of drug prescription during pregnancy in France from 2011 to 2014 using the permanent sample of the French national computerized healthcare database and with a focus on recommended supplementations, fetotoxic drugs and teratogenic drugs.MethodsAll pregnancies identified by the International Classification of Diseases, 10th Revision codes list in the hospitalization database, lasting more than 9 weeks of amenorrhea and whose delivery occurred between 01/01/2011 and 12/31/2014, were included. Drugs delivered between the trimester before and until the end of the pregnancy were included. Drug exposure prevalence was calculated for …

DrugAdultPediatricsmedicine.medical_specialtypharmacoepidemiologyPrescription drugPrescription DrugsNational Health ProgramsEpidemiologymedia_common.quotation_subject[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics030226 pharmacology & pharmacy03 medical and health sciencesYoung Adult0302 clinical medicinePregnancymedicineHumansPharmacology (medical)Medical prescriptionPregnancy Trimestersmedia_commonPregnancy030219 obstetrics & reproductive medicinebusiness.industrydrug recommendationsadministrative healthcare databasePharmacoepidemiologymedicine.diseaseDrug classTeratogensprescription medicationsAmenorrheaFemaleFrancePregnancy Trimestersmedicine.symptombusinessPharmacoepidemiology and drug safety
researchProduct